Intelligent Pharmacy: Leveraging AI and Automation to Enhance Patient Care and Pharmacist Roles

Artificial intelligence (AI) and automation are transforming pharmacy practice, offering new opportunities to enhance clinical care, operational efficiency, and workforce optimization. Although nearly 50% of global health care organizations plan to integrate AI by 2025,¹ successful implementation requires clarity on stakeholder roles, benefits, and barriers. This article targets clinicians, pharmacy students, and health care administrators, providing an overview of technological advances, workforce implications, and educational needs in the evolving pharmacy landscape.

AI and Automation in Today’s Pharmacy Operations

reshaping hospital and retail pharmacy settings. Hospitals utilize automated dispensing cabinets, robotic intravenous compounding, radio frequency identification inventory systems, and AI-driven analytics for order verification.² Basic analytics, including use of data from smart pumps, clinical decision support, or automation in dispensing and compounding, have been deployed by 87.3% of hospitals.³ In addition, up to 73% of hospitals now use innovative verification tools for prescription processing,⁴ enabling remote oversight and low-risk auto-approvals while still routing high-alert medications for manual pharmacist review.⁵ Robotic compounding systems reduce waste, support supply chain resilience, and improve safety.

Retail chains are adopting similar innovations on a scale. CVS leverages centralized AI and robotics to serve more than 9000 stores,⁶ whereas Walgreens uses centralized robotic hubs that now fill 60% of prescriptions for approximately 3000 stores.⁷ Walmart’s facilities process up to 100,000 prescriptions daily, with plans to support 90% of its stores by 2026.⁸ This automation supports higher prescription volumes while decreasing dispensing errors and enabling faster turnaround.

Benefits for Clinicians and Health Systems

Key benefits of automation and AI include reduced medication errors, decreased wait times, and enhanced patient satisfaction, with a 15% to 22% improvement in pharmacy-related scores.^9,10 Pharmacist productivity increases by up to 33%, and central fill models reduce error rates to nearly 0% compared with manual methods.^10,11

The most transformative shift is in redeploying pharmacists to higher-value clinical roles. In automated environments, pharmacists report spending up to 45% more time on patient-facing care such as medication therapy management and chronic disease counseling.¹² Walmart’s automation led to a 30% increase in pharmacist-patient engagement by offloading routine tasks.⁸

For administrators, automation represents not only efficiency but also a retention strategy. In a time of widespread labor shortages, AI and automation reduce workload strain, minimize burnout, and attract pharmacists interested in advanced practice roles.

Challenges: A Balanced Perspective

Despite key advantages, automation and AI integration are not without challenges. Initial investment costs can be prohibitive for smaller institutions. Installation and maintenance of robotic systems, staff retraining, and integration with electronic health records require significant capital and time.¹³ Furthermore, change resistance among pharmacy teams and clinical partners may arise from perceived threats to job roles or discomfort with technology.¹⁴

Cybersecurity is another critical concern. As automation increasingly relies on cloud-based AI tools, safeguarding sensitive patient and prescription data must be prioritized.¹⁵ Health care organizations must also develop clear protocols for algorithm transparency, validation, and clinical oversight to prevent reliance on flawed or biased systems.^16,17

These realities highlight the importance of thoughtful planning, stakeholder engagement, and evidence-based implementation strategies.

Preparing Emerging Pharmacists for the AI Era

Pharmacy students and early-career professionals must be equipped to work in technology-driven environments. Curricula should incorporate training in digital literacy, data interpretation, and health informatics.¹⁸ Competency in working alongside automated systems, understanding AI outputs, and contributing to technology governance will be vital.¹⁹

Pharmacy schools should also foster interdisciplinary collaboration, teaching students to integrate AI tools into patient care teams and advocate for evidence-based deployment. Experiential rotations in automated or AI-enhanced settings can help students gain firsthand exposure to evolving workflows and clinical decision support tools.²⁰

Emerging pharmacists who understand both clinical and digital domains will be uniquely positioned to lead AI integration initiatives in practice settings.²¹

Future Directions: Strategic Integration and Ethical Oversight

AI applications are expected to become more advanced, assisting with drug interaction checks, clinical documentation, and patient education materials. Tools such as OpenEvidence support real-time literature analysis and care recommendations, assisting pharmacists in evidence-based practices.²²

However, AI tools are only as good as the data and logic underpinning them. Pharmacists must remain central to development and implementation, ensuring that clinical context, patient safety, and ethical considerations remain paramount. When used appropriately, AI can support, but never replace, the nuanced, human-centered care that pharmacists provide. Empathy, communication, and judgment remain irreplaceable.

Conclusion

AI and automation are redefining the pharmacy workflow, enabling clinicians to operate at the top of their license, improving system efficiency, and enhancing patient outcomes. Successful adoption, however, requires more than technology. It demands a balanced approach that acknowledges costs, barriers, and the need for ongoing training. By empowering pharmacists and students to engage proactively with these tools, the profession can lead this transformation and ensure that innovation translates into patient impact.

REFERENCES

1. Mental illness. National Institute of Mental Health. Updated September 2024. Accessed June 24, 2025. https://www.nimh.nih.gov/health/statistics/mental-illness

2. Protecting Youth Mental Health: The US Surgeon General’s Advisory. US Department of Health and Human Services; 2021. Accessed June 24, 2025. https://www.hhs.gov/surgeongeneral/reports-and-publications/youth-mental-health/index.html

3. Pedrelli P, Nyer M, Yeung A, Zulauf C, Wilens T. College students: mental health problems and treatment considerations. Acad Psychiatry. 2015;39(5):503-511. doi:10.1007/s40596-014-0205-9

4. Czeisler MÉ, Lane RI, Petrosky E, et al. Mental health, substance use, and suicidal ideation among US adults during the COVID-19 pandemic — United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1049-1057. doi:10.15585/mmwr.mm6932a1

5. 2022 National Survey on Drug Use and Health (NSDUH). Substance Abuse and Mental Health Services Administration; 2023. Accessed June 24, 2025. https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health

6. Mental health – United States. Statista. 2025. Accessed June 24, 2025. https://www.statista.com/outlook/hmo/mental-health/united-states

7. Mental Health & Substance Abuse Centers in the US – Market Research Report (2015-2030). IBISWorld. Updated June 2025. Accessed June 24, 2025. https://www.ibisworld.com/united-states/market-research-reports/outpatient-mental-health-substance-abuse-centers-industry/

8. Mental Health America. The State of Mental Health in America. Accessed June 24, 2025. https://mhanational.org/issues/state-mental-health-america

9. Buntz B. The pandemic is fueling the demand for natural alternatives to antidepressants. Drug Discovery and Development. July 19, 2022. Accessed June 25, 2025. https://www.drugdiscoverytrends.com/the-pandemic-is-fueling-the-demand-for-natural-alternatives-to-antidepressants/

10. Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Obstet Gynecol Clin North Am. 2009;36(4):789-807. doi:10.1016/j.ogc.2009.10.005

11. Kimble C, Coustasse A. The promise of psilocybin assisted therapy for opioid use disorder. Pharmacy Times. May 15, 2025. Accessed June 25, 2025. https://www.pharmacytimes.com/view/the-promise-of-psilocybin-assisted-therapy-for-opioid-use-disorder

12. National Alliance on Mental Illness. Distribution of agreement with the following statements regarding a mental health crisis in the US as of 2023. Statista. July 13, 2023. Accessed June 24, 2025. https://www.statista.com/statistics/1417462/views-on-managing-a-mental-health-crisis-in-the-us/

13. Social Determinants of Mental Health. World Health Organization; 2025. Accessed June 24, 2025. https://www.who.int/publications/i/item/9789241506809

14. The 2023 Annual Homeless Assessment Report (AHAR) to Congress. US Department of Housing and Urban Development; 2023. Accessed June 24, 2025. https://www.huduser.gov/portal/sites/default/files/pdf/2023-AHAR-Part-1.pdf

15. Journal of the American Medical Association. Percentage of select US demographic groups who reported symptoms of serious psychological distress in 2018 and during COVID-19 pandemic*. Statista. June 3, 2020. Accessed June 24, 2025. https://www.statista.com/statistics/1174188/covid-psychological-distress-us-and-covid-impact-by-group/

16. National Institute for Health and Welfare. Share of people with significant psychological distress according to the MHI-5 scales* in Finland in 2018, by level of education. Statista. May 14, 2019. Accessed June 24, 2025. https://www.statista.com/statistics/1022631/share-people-significant-psychological-distress-mhi-5-scale-education-level-finland/

17. Czeisler MÉ, Lane RI, Petrosky E, et al. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic – United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1049-1057. doi:10.15585/mmwr.mm6932a1

18. El-Den S, Collins JC, Chen TF, O’Reilly C.
    Pharmacists’ roles in mental healthcare: past, present and future. Pharm Pract (Granada). 2021;19(3):2545. doi:10.18549/PharmPract.2021.3.2545

19. Finley PR, Crismon ML, Rush AJ. Evaluating the impact of pharmacists in mental health: a systematic review. Pharmacotherapy. 2003;23(12):1634-1644. doi:10.1592/phco.23.15.1634.31952

20. Trenaman SC, Kennie-Kaulbach N, d’Entremont-MacVicar E, et al. Implementation of pharmacist-led deprescribing in collaborative primary care settings. Int J Clin Pharm. 2022;44:1216-1221. doi:10.1007/s11096-022-01449-w

21. Rubio-Valera M, Chen TF, O’Reilly CL. New roles for pharmacists in community mental health care: a narrative review. Int J Environ Res Public Health. 2014;11(10):10967-10990. doi:10.3390/ijerph111010967

22. Crespo-Gonzalez C, Dineen-Griffin S, Rae J, Hill R. Mental health training programs for community pharmacists, pharmacy staff and students: a systematic review. Res Social Adm Pharm. 2022;18(11):3895-3910. doi:10.1016/j.sapharm.2022.06.006